Observational studyBMC surgery2026
Use of microfragmented autologous adipose tissue (LIPOGEMS®) as a sphincter-saving therapy for complex anal fistulas: a single-center retrospective study.
Observational study in BMC surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundComplex anal fistulas remain a therapeutic challenge due to high recurrence rates and the risk of incontinence associated with conventional treatments. Microfragmented autologous adipose tissue has emerged as a sphincter-sparing option with potential regenerative and anti-inflammatory properties. This study aimed to evaluate the safety and efficacy of its injection into the fistula tract combined with closure of the internal opening.
methodsA single-center, retrospective, observational study was conducted between June 2019 and May 2025. All patients with complex anal fistulas treated with microfragmented adipose tissue processed with LIPOGEMS® system were included. Demographic data, fistula characteristics, surgical history, perioperative variables, postoperative morbidity, healing rate, and hospital stay were analyzed. Follow-up visits were performed weekly in the first month, and at 3, 6 and 12 months thereafter.
resultsA total of 28 patients with complex fistula were included. Mean patient age was 51.2 years (SD: 15.3), with predominance of males (69.7%). Most fistulas were medium or high transsphincteric (85.7%) and the main location was posterior (57.1%). 75% of patients had undergone previous curative-intent procedures. Median operative time was 71 minutes, and median processed adipose volume was 14 ml. Two postoperative complications were recorded (one abdominal hematoma-CD I and one perianal abscess-CD IIIa). After a median follow-up of 11.2 months, the overall healing rate was 46.4%, higher in primary (57.1%) and posterior fistulas (56.3%). Median hospital stay was one day, and median clinical closure occurred at 2.7 months.
conclusionsLIPOGEMS® therapy appeared safe, feasible, and associated with encouraging healing outcomes, offering advantages in functional preservation and recovery. Larger prospective studies are needed to confirm these results and refine its role in fistula management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.